Inovalon (INOV) Gets a Hold Rating from Robert W. Baird


Robert W. Baird analyst Matthew Gillmor reiterated a Hold rating on Inovalon (NASDAQ: INOV) today and set a price target of $10. The company’s shares opened today at $12.95.

According to TipRanks.com, Gillmor is a 5-star analyst with an average return of 15.6% and a 66.0% success rate. Gillmor covers the Services sector, focusing on stocks such as Encompass Health Corporation, Addus Homecare Corp, and Envision Healthcare.

Inovalon has an analyst consensus of Hold, with a price target consensus of $10.

See today’s analyst top recommended stocks >>

Based on Inovalon’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.27 million. In comparison, last year the company had a net profit of $5.34 million.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INOV in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovalon Holdings, Inc. engages in the development of cloud-based platforms for the healthcare industry. Its products include datasets, integration technologies, predictive analytics, and related services. The company was founded on September 11, 2014 and is headquartered in Bowie, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts